Patients with non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) clearly benefit from EGFR–tyrosine kinase inhibitor (EGFR-TKI) therapy (1). The gene discussed is EGFR; the disease is lung cancer.